Global ETD Search

Search theses and dissertations gathered from participating repositories worldwide. Every result links back to the library that holds it. No account is needed.

Results

Showing 1 to 20 of 66 for “"Spironolactone"”.

  1. The Effect of Spironolactone on Cerebral Blood Flow and Cognition

    … the effects are potentially reversible by spironolactone (Spiro) reducing blood pressure (BP) and arterial stiffness. This thesis consisted of a double-blind, controlled trial with older hypertensive adults (OA) who were receiving stable treatment with centrally acting angiotensin …

    waterloo Repository record for The Effect of Spironolactone on Cerebral Blood Flow and Cognition (opens in a new tab)

  2. Repurposing Spironolactone as a Survivin Targeting Therapeutic in Canine Osteosarcoma

    … therapeutic target. This thesis investigated spironolactone, a mineralocorticoid receptor antagonist, as a repurposed anti-cancer and chemosensitizing agent in cOSA. Abrams and D17 cells were treated with spironolactone alone or combined with carboplatin, doxorubicin, paclitaxel, or …

    guelph Repository record for Repurposing Spironolactone as a Survivin Targeting Therapeutic in Canine Osteosarcoma (opens in a new tab)

  3. The effect of spironolactone on cardiovascular disease in early stage chronic kidney disease

    … the arteries, heart and kidney. Treatment with spironolactone, which blocks aldosterone at the mineralocorticoid receptor might be effective at reducing such injury. To address these hypotheses, I performed an observational study in patients with early stage CKD without known cardiovascular …

    birmingham Download PDF for The effect of spironolactone on cardiovascular disease in early stage chronic kidney disease (opens in a new tab)

  4. Spironolactone to treat hypertension in end-stage renal disease : analysis of effectiveness and safety

    … from continued renal cellular damage⁸⁻¹⁰. Spironolactone, an aldosterone antagonist, has the potential to provoke hyperkalemia. Consequently, current guidelines do not recommend spironolactone to manage hypertension in ESRD because of this risk⁶⁻⁷. Our primary objectives were to determine …

    texas Repository record for Spironolactone to treat hypertension in end-stage renal disease : analysis of effectiveness and safety (opens in a new tab)

  5. The effect of spironolactone on exercise capacity in functionally impaired older people without heart failure

    … of the renin-angiotensin-aldosterone system with spironolactone would improve physical function in older people without heart failure. In a double-blind, randomised controlled clinical trial 120 participants, aged >65 years with functional impairment were randomized to receive 25mg spironolactone …

    dundee Repository record for The effect of spironolactone on exercise capacity in functionally impaired older people without heart failure (opens in a new tab) Download PDF for The effect of spironolactone on exercise capacity in functionally impaired older people without heart failure (opens in a new tab)

  6. ASSESSING POTENTIALLY INAPPROPRIATE MEDICATION USE IN PATIENTS AT RISK FOR ADVERSE DRUG EFFECTS: SPIRONOLACTONE AS A CASE STUDY

    … patient kidney function. One such medication, spironolactone, an aldosterone antagonist indicated for heart failure, has been demonstrated in clinical trials to reduce morbidity and mortality among individuals with normal renal function, but its safety in those with chronic kidney disease (CKD) …

    jhu Repository record for ASSESSING POTENTIALLY INAPPROPRIATE MEDICATION USE IN PATIENTS AT RISK FOR ADVERSE DRUG EFFECTS: SPIRONOLACTONE AS A CASE STUDY (opens in a new tab)

  7. Phase II 6-month cyclic progesterone/spironolactone pilot therapy trial in polycystic ovary syndrome—a pre-post one-arm feasibility study

    … a 6-month treatment with cyclic progesterone and spironolactone on health-related quality of life in women with androgenic PCOS. Methods: A 6-month open-label, pre-post pilot study was conducted with 26 participants (mean age 29 ± 4.9 years, BMI 30.3 ± 8.1 kg/m², 61.5% White). Within-woman changes …

    ubc Repository record for Phase II 6-month cyclic progesterone/spironolactone pilot therapy trial in polycystic ovary syndrome—a pre-post one-arm feasibility study (opens in a new tab) Download PDF for Phase II 6-month cyclic progesterone/spironolactone pilot therapy trial in polycystic ovary syndrome—a pre-post one-arm feasibility study (opens in a new tab)

  8. Role of aldosterone in cardiac remodeling post-myocardial infarction and after high salt diet

    … or high salt (8%) diet, either without or with spironolactone (20 or 80 mg/kg/day) were given to Wistar rats for 4 and 8 weeks. Both LV weight and cardiomyocyte cross-sectional diameter were increased significantly by high salt diet after 4 and 8 weeks. Both LV and right ventricle (RV) collagen …

    ottawa-retro Repository record for Role of aldosterone in cardiac remodeling post-myocardial infarction and after high salt diet (opens in a new tab)

  9. Μελέτη της επίδρασης της σπιρονολακτόνης στη έκφραση γονιδίων που σχετίζονται με τη μυοκαρδιακή ίνωση σε υπερτασικούς επιίμυες

    … of mineralocorticoid receptor – and specifically spironolactone - reduces cardiac fibrosis include the downregulation of mRNA expression of angiotensinogen converting enzyme, the reduction of aldosterone - induced collagen production by cardiac fibroblasts and the prevention of perivascular …

    greece Repository record for Μελέτη της επίδρασης της σπιρονολακτόνης στη έκφραση γονιδίων που σχετίζονται με τη μυοκαρδιακή ίνωση σε υπερτασικούς επιίμυες (opens in a new tab)

  10. Mineralocorticoid receptor involvement in vascular dysfunction associated with vascular injury

    … late-stage diabetes. MR inhibition with spironolactone treatment improved coronary endothelium-dependent vasodilation in OLETF rats. Further, RNA sequencing of aortas from Spironolactone-treated OLETF rats revealed 157 differentially expressed genes predicting MR involvement in …

    missouri Repository record for Mineralocorticoid receptor involvement in vascular dysfunction associated with vascular injury (opens in a new tab)

  11. Aldosterone-induced endothelial glycocalyx dysfunction, a potential therapeutic target in proteinuria?

    … organ damage in heart failure and renal disease. Spironolactone, a mineralocorticoid receptor inhibitor, slows disease progression but side effects including hyperkalemia limit its use. Damage to the endothelial glycocalyx (a luminal biopolymer layer) has been implicated in pathogenesis of …

    bristol Repository record for Aldosterone-induced endothelial glycocalyx dysfunction, a potential therapeutic target in proteinuria? (opens in a new tab) Download PDF for Aldosterone-induced endothelial glycocalyx dysfunction, a potential therapeutic target in proteinuria? (opens in a new tab)

  12. New drugs in prevention of experimental corneal graft rejection

    … receptor agonist (SEGRA), everolimus and spironolactone on the prevention of allograft rejection in a MHC class I/II mismatch rat corneal transplant model. Methods: A total of 133 female Lewis rats underwent PKP. Syngeneic corneal grafting in 20 rats served as control for technical …

    fu-berlin Repository record for New drugs in prevention of experimental corneal graft rejection (opens in a new tab)

  13. Paediatric drug development:reformulation, in vitro, genomic and in vivo evaluation

    … and the potassium-sparing diuretic spironolactone was selected from the NHS specials list for November 2011 drug tariff with the view to produce oral liquid formulations providing dosage forms targeting paediatrics. Lisinopril, ramipril and spironolactone were chosen for their …

    aston Download PDF for Paediatric drug development:reformulation, in vitro, genomic and in vivo evaluation (opens in a new tab)

  14. Mineralocorticoid-receptor antagonism and its metabolic consequences in haemodialysis patients

    … was set up to investigate the effect of 50 mg of spironolactone once daily on left ventricular mass index in haemodialysis patients and several secondary endpoints. This dissertation reports findings from the MiREnDa trial on (a) the efficacy of spironolactone to influence serum levels of …

    wurz-thes Repository record for Mineralocorticoid-receptor antagonism and its metabolic consequences in haemodialysis patients (opens in a new tab)

  15. Monocyte subsets in atrial fibrillation with preserved left ventricular function

    … 4) markers of cardiac fibrosis, 5) utility of Spironolactone to aid in improved exercise capacity in this cohort of patients. Methods: Monocyte subsets were analysed by flow cytometry on venous blood samples in 250 patients with permanent atrial fibrillation and preserved left ventricular …

    birmingham Download PDF for Monocyte subsets in atrial fibrillation with preserved left ventricular function (opens in a new tab)

  16. Role of aldosterone and the aldosterone binding globulin in experimental and spontaneous hypertension

    … by adrenalectomy or administration of a spironolactone but not by adrenalectomy when physiological amounts of aldosterone were concomitantly administered with ABG-TsU The elevated BP in rats treated with ABG-TsU for two weeks was due to increased cardiac output since total peripheral …

    ubc Repository record for Role of aldosterone and the aldosterone binding globulin in experimental and spontaneous hypertension (opens in a new tab) Download PDF for Role of aldosterone and the aldosterone binding globulin in experimental and spontaneous hypertension (opens in a new tab)

  17. Electrolyte Metabolism During the Oestrous Cycle in the Rat

    … rate was observed during the oestrous cycle. Spironolactone blocked the increased sodium and water retention and potassium excretion observed at oestrus, but had little effect on renal electrolyte function in dioestrous or ovariectomised animals. Spironolactone has been shown to inhibit the …

    aston Repository record for Electrolyte Metabolism During the Oestrous Cycle in the Rat (opens in a new tab) Download PDF for Electrolyte Metabolism During the Oestrous Cycle in the Rat (opens in a new tab)

  18. Endocrinology of equine metabolic pathophysiology

    … the mineralocorticoid receptor antagonist spironolactone to pony mares. We found no change in cortisol or leptin concentrations between treatments, but did see a trend for increased aldosterone concentrations in the blood of spironolactone treated ponies over time. Further work is necessary …

    missouri Repository record for Endocrinology of equine metabolic pathophysiology (opens in a new tab)

Page 1 of 4